Advancing a new class of programmable, logic-gated DNA-protein therapeutics
About
Plectonic Biotech
Plectonic Biotech’s new class of programmable DNA-protein therapeutics function as molecular logic gates to selectively direct the immune response to the tumor. By applying our modular LOGIBODY® platform, we are building a pipeline of multi-specific T-cell-engaging biologics designed to overcome off-target toxicity and exponentially improve the therapeutic impact of immunotherapies using clinically validated targets. Initially focused on hematologic malignancies, our approach is designed to deliver an unprecedented level of precision and control, broadening the therapeutic window and improving patient outcomes in both liquid and solid tumors.
Our Technology
LOGIBODY® molecules provide a novel approach to disease treatment by combining the specificity of antibody-based targeting with the enhanced stability and modularity of DNA scaffolding.
This cutting-edge innovation enables precision targeting of disease mechanisms with unmatched efficiency.
Pipeline
Our development pipeline is focused on breakthrough immunotherapies. By leveraging our advanced molecular design, we aim to bring first-in-class therapeutics to clinical applications.
